Eli Lilly agreed to acquire Adverum in a deal focused on ixoberogene soroparvovec (ixo‑vec), a Phase III, single‑dose AAV gene therapy for wet age‑related macular degeneration (wAMD). Lilly said the purchase advances its sensory therapeutics strategy and preserves Adverum’s trials and team. Ixo‑vec is engineered to provide continuous intraocular aflibercept exposure from a single intravitreal injection, aiming to replace chronic anti‑VEGF dosing. Lilly emphasized clinical and commercial rationale tied to reducing patient burden and expanding its ophthalmology portfolio. The deal highlights Big Pharma appetite for one‑time gene therapies that address chronic indications; it also reflects acquirers’ willingness to assume technical and regulatory risk to secure differentiated, durable treatment prospects.